Actividad docente: Acreditada como Profesor Contratado Doctor por la ANECA desde septiembre del 2014. Colaboradora docente de la Universidad de Barcelona tanto en docencia pregrado como postgrado. Co directora de 2 trabajos de final de grado en 2014 y en 2017 y Co directora de Tesina Final de Master en 2013.
Estancias en centros extranjeros: Chelsea and Westminster Hospital NHS Fundation Trust Imperial Collage. Responsable Anton L Pozniak, Duración 6 meses en 2010 como parte de la estancia en el extranjero del contrato Rio Hortega y 6 meses en 2015 como parte de la estancia en el extranjero del contrato Sara Borrell.
Premio Extraordinario de Doctorado por la Universidad Autónoma de Barcelona.
Ponente en el Congreso Catalan de Medicina Interna en Barcelona,  Junio 2016 y en 10th Neuropsichiatry and HIV International Symposium, Barcelona, Mayo 2017.
Otros contratos y proyectos como investigadora asociada: Ensayos clínicos multicéntricos
1.INTERLEUKIN-2 PLUS ANTIRETROVIRAL THERAPY FOR HIVINFECTED PATIENTS WITH LOW CD4+ COUNTS (SILCAAT STUDY) CLINICALTRIALS.GOV IDENTIFIER: NCT00013611.
2. AN INTERNATIONAL STUDY TO EVALUATE RECOMBINANT INTERLEUKIN-2 IN HIV POSITIVE PATIENTS TAKING ANTIRETROVIRAL THERAPY (ESPRIT): NCT00004978
3. EFFECT OF INTERMITTENT ALDESLEUKIN TREATMENT WITH OR WITHOUT ANTI-HIV DRUGS IN HIV INFECTED PEOPLE (STALWART): NCT00110812
4. BMS-REYATAZ STUDY IN TREATMENT IN NAIVE SUBJECTS TO COMPARE THE EFFICACY AND SAFETY BETWEEN BOOSTED REYATAZ AND KALETRA WHEN IN COMBINATION WITH FIXED DOSE TRUVADA : NCT00272779
5. ASSERT Study : NCT00549198
6. NEVIRAPINE VS.ATAZANAVIR BOOSTED WITH RITONAVIR ON A BACKGROUND OF TRUVADA IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED
NAIVE PATIENTS (NEWART) : NCT00552240
5. HIV-1 INFECTION STUDY OF ONCE A DAY VERSUS TWICE A DAY PROTEASE INHIBITOR IN ANTIRETROVIRAL TREATMENT NAIVE ADULTS :NCT00450580
6. STUDY OF LOPINAVIR/RITONAVIR TABLETS VERSUS SOFT GEL CAPSULES AND ONCE DAILY VERSUS TWICE DAILY ADMINISTRATION, WHEN COADMINISTERED WITH NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS IN ANTIRETROVIRAL NAIVE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED SUBJECTS : NCT00262522
7. A CLINICAL TRIAL COMPARING THE EFFICACY OF DARUNAVIR/RITONAVIR MONOTHERAPY VERSUS A TRIPLE COMBINATION THERAPY CONTAINING DARUNAVIR/RITONAVIR AND 2 NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS IN PATIENTS WITH UNDETECTABLE PLASMA HIV-1 RNA ON CURRENT TREATMENT (PROTEA) : NCT01448707
8. STUDY TO EVALUATE THE ACTIVITY AND TOLERABILITY OF LOPINAVIR/RITONAVIR AND LAMIVUDINE BITHERAPY IN HIV PATIENTS WITH VIRAL SUPPRESSION (OLE) : NCT01471821
9. DURABILITY OF VIROLOGIC RESPONSE AND/ OR VIRAL RESISTANCE PATTERNS IN PARTICIPANTS WITH CHRONIC HEPATITIS C WHO HAVE BEEN PREVIOUSLY TREATED WITH MK-5172 (MK-5172-017) : NCT01667081
10. A STUDY OF THE COMBINATION REGIMEN MK-5172 AND MK-8742 ± RIBAVIRIN IN PARTICIPANTS WITH CHRONIC HEPATITIS C (MK-5172-035) (C-WORTHY) : NCT01717326
11. AN EFFICACY AND SAFETY STUDY OF MK-5172 + MK-8742 IN THE TREATMENT OF CHRONIC HEPATITIS C VIRUS IN PARTICIPANTS WHO ARE CO-INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (C-EDGE COINFECTION) (MK-5172-061) : NCT02105662
12. A STUDY TO EVALUATE SAFETY AND EFFICACY OF BOCEPREVIR-RESPONSE GUIDED THERAPY IN CONTROLLED HIV PATIENTS WITH CHRONICHEPATITIS C GENOTYPE 1 INFECTION WHO FAILED PREVIOUSLY TO PEGINTERFERON /RIBAVIRIN: NCT01718301
13. GILEAD SUSTAINED VIROLOGIC RESPONSE (SVR) REGISTRY: NCT01457755